FIBERGRAFT BG MATRIX
-
Biologics
Prosidyan® FIBERGRAFT® Achieves High Fusion Rate in Multi-Center Clinical Study Presented at Top Neurosurgery Conference
FIBERGRAFT® BG Matrix Achieved 96.3% Fusion Rate in Posterolateral Spine Fusion Clinical Study NEW PROVIDENCE, N.J. (PRWEB) AUGUST 26, 2021 Prosidyan,…
Read More » -
Biologics
Prosidyan Announces FDA Clearance and Commercial Launch of Its FIBERGRAFT BG MATRIX for Poster-Lateral Spinal Fusion
Warren, NJ, October 26, 2017 –(PR.com)– NJ-based Prosidyan (www.prosidyan.com), developer of proprietary fiber-based bioactive glass products, announced today FDA 510(k)…
Read More »